Active surveillance is not "doing nothing." It is a carefully structured monitoring programme that avoids immediate treatment for low-risk prostate cancer — while maintaining the option to treat at any point if the cancer changes behaviour.
You have been diagnosed with prostate cancer. Your urologist has recommended active surveillance — not surgery, not radiation, but monitoring. You are understandably alarmed. How can the right approach be to watch cancer and do nothing?
This is one of the most misunderstood concepts in prostate oncology. Active surveillance does not mean ignoring cancer. It means recognising that for a specific subset of prostate cancers — those that are very unlikely to progress in a patient's lifetime — the harm from immediate treatment can exceed the benefit.
1. What is active surveillance?
Active surveillance (AS) is an evidence-based management strategy for low-risk prostate cancer. The cancer is diagnosed and confirmed — but instead of treating it immediately, it is monitored with structured, regular testing: PSA checks, mpMRI scans, and repeat biopsies.
The rationale is grounded in biology. Grade Group 1 (Gleason 6) prostate cancer — the vast majority of patients on AS — has an exceptionally low metastatic potential. Large studies following thousands of men on active surveillance for 10–15 years show that cancer-specific mortality is under 1–2%. The cancer is real, but it behaves like a chronic, stable condition rather than an aggressive threat.
Before PSA screening became widespread, prostate cancer was typically diagnosed at an advanced stage and treatment was clearly beneficial. PSA screening now detects many low-grade cancers that would never have caused harm in a patient's lifetime. Treating all of these with surgery or radiation causes real side effects — incontinence, erectile dysfunction — for men who would never have needed treatment. Active surveillance was developed to avoid this overtreatment.
2. Active surveillance vs watchful waiting
- No structured monitoring protocol
- Treatment only if symptoms develop
- Used in men with limited life expectancy
- Palliative intent if cancer progresses
- Structured PSA, MRI, and biopsy protocol
- Curative treatment immediately if progression detected
- Used in men with many years ahead
- Curative intent — deferred, not abandoned
3. Who is a candidate for active surveillance?
Eligibility criteria vary slightly between institutions, but the typical AS candidate has:
- Grade Group 1 (Gleason 6, 3+3=7): The primary criterion. GG1 disease has minimal metastatic potential.
- PSA below 10–15 ng/mL: Low PSA supports low-burden disease.
- Limited biopsy involvement: Fewer than 50% of cores positive, and low percentage involvement per core.
- Clinical stage T1–T2a: No extension beyond the prostate capsule on clinical examination or MRI.
- Life expectancy >10 years: AS is a long-term commitment — it makes sense for men who could realistically develop problematic cancer within their lifetime.
Selected Grade Group 2 (Gleason 3+4=7) patients — particularly older men with small-volume disease — may also be managed on AS, but this requires careful discussion and a higher-intensity monitoring protocol.
4. The monitoring protocol
PSA every 3–6 months
Regular PSA monitoring detects rising values that may indicate progression. PSA doubling time — how quickly the PSA is doubling — is the key metric. A doubling time under 3 years is a trigger for reassessment.
mpMRI at 12 months, then every 1–3 years
MRI monitors for changes in the appearance of the index lesion and for the development of new lesions. A new or growing suspicious lesion triggers a targeted rebiopsy.
Repeat biopsy at 1–2 years, then every 3–5 years
A confirmatory biopsy — ideally MRI-targeted — at 12 months confirms that the initial biopsy did not underestimate the grade. Subsequent biopsies monitor for grade reclassification.
Annual clinic review
Regular urologist review to assess clinical examination, discuss PSA trends, and address any patient concerns or changes in preference. AS is a partnership between patient and clinician.
5. What triggers a change to treatment?
Active surveillance does not mean passive acceptance. The monitoring programme is designed to detect changes early — when curative treatment is still fully effective. The following findings typically trigger treatment:
Grade reclassification to Grade Group 3 or above on repeat biopsy · PSA doubling time under 3 years · New high-PIRADS lesion on MRI · Patient anxiety that makes continued AS psychologically unsustainable · Change in cancer volume on biopsy
If any of these triggers are met, treatment — surgery or radiation — is offered. Because the cancer has been closely monitored throughout, conversion to treatment is done at a curative stage. The window for curative treatment is not missed by being on AS.
6. Managing the anxiety of living with untreated cancer
The most common reason men leave active surveillance early is psychological — the discomfort of knowing they have cancer that is not being treated. This is a completely legitimate concern that should be addressed openly, not dismissed.
Large, long-term studies — including the ProtecT trial — show that men on active surveillance have the same cancer-specific survival as those who received immediate surgery or radiation. The cancer is not getting ahead while you wait. The monitoring is working. Understanding this fundamentally changes the psychological experience of AS.
- Know the numbers: Grade Group 1 prostate cancer has a 15-year cancer-specific survival exceeding 97%. These are genuinely reassuring statistics, not dismissals of your diagnosis.
- Take part actively: The word "active" in active surveillance matters. Attend every appointment, every PSA test, every biopsy. Feeling in control reduces anxiety.
- Talk to your surgeon: Your preference matters. If after thorough understanding of the evidence you still prefer treatment, that is a valid decision. AS is a recommendation, not a mandate.
- Am I a confirmed candidate — has my biopsy been reviewed by a specialist uropathologist?
- What monitoring schedule will I be on — PSA, MRI, and repeat biopsy intervals?
- What specifically would trigger treatment — what numbers or findings are you watching for?
- What is the risk I will need treatment within 5 years — and within 10?
- If I convert to treatment, will curative options still be available?
- Can you share the data from your centre on AS outcomes?
This article is for general patient education about active surveillance. Eligibility, monitoring protocols, and trigger thresholds vary by institution and individual risk. Active surveillance is not appropriate for all prostate cancers. Discuss your specific situation with your urologist.